vs
NEUROCRINE BIOSCIENCES INC（NBIX）与利氏兄弟拍卖行（RBA）财务数据对比。点击上方公司名可切换其他公司
利氏兄弟拍卖行的季度营收约是NEUROCRINE BIOSCIENCES INC的1.5倍（$1.2B vs $805.5M），NEUROCRINE BIOSCIENCES INC净利率更高（19.1% vs 9.1%，领先10.0%），NEUROCRINE BIOSCIENCES INC同比增速更快（28.3% vs 5.4%），NEUROCRINE BIOSCIENCES INC自由现金流更多（$386.0M vs $186.5M），过去两年NEUROCRINE BIOSCIENCES INC的营收复合增速更高（25.0% vs 6.3%）
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
利氏兄弟拍卖行（股票代码RBA）是全球知名的工业资产拍卖服务商，注册地位于加拿大，属公开上市企业，总部设在美国伊利诺伊州韦斯特切斯特，普通股同时在多伦多证券交易所与纽约证券交易所挂牌交易。
NBIX vs RBA — 直观对比
营收规模更大
RBA
是对方的1.5倍
$805.5M
营收增速更快
NBIX
高出22.9%
5.4%
净利率更高
NBIX
高出10.0%
9.1%
自由现金流更多
NBIX
多$199.5M
$186.5M
两年增速更快
NBIX
近两年复合增速
6.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $805.5M | $1.2B |
| 净利润 | $153.7M | $109.7M |
| 毛利率 | 97.8% | — |
| 营业利润率 | 26.2% | 14.7% |
| 净利率 | 19.1% | 9.1% |
| 营收同比 | 28.3% | 5.4% |
| 净利润同比 | 49.1% | -7.4% |
| 每股收益（稀释后） | $1.49 | $0.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NBIXRBA
| Q4 25 | $805.5M | $1.2B | ||
| Q3 25 | $794.9M | $1.1B | ||
| Q2 25 | $687.5M | $1.2B | ||
| Q1 25 | $572.6M | $1.1B | ||
| Q4 24 | $627.7M | $1.1B | ||
| Q3 24 | $622.1M | $981.8M | ||
| Q2 24 | $590.2M | $1.1B | ||
| Q1 24 | $515.3M | $1.1B |
净利润NBIXRBA
| Q4 25 | $153.7M | $109.7M | ||
| Q3 25 | $209.5M | $95.5M | ||
| Q2 25 | $107.5M | $109.8M | ||
| Q1 25 | $7.9M | $113.4M | ||
| Q4 24 | $103.1M | $118.5M | ||
| Q3 24 | $129.8M | $76.1M | ||
| Q2 24 | $65.0M | $111.1M | ||
| Q1 24 | $43.4M | $107.4M |
毛利率NBIXRBA
| Q4 25 | 97.8% | — | ||
| Q3 25 | 98.2% | — | ||
| Q2 25 | 98.4% | — | ||
| Q1 25 | 98.4% | — | ||
| Q4 24 | 98.5% | — | ||
| Q3 24 | 98.7% | — | ||
| Q2 24 | 98.4% | — | ||
| Q1 24 | 98.5% | — |
营业利润率NBIXRBA
| Q4 25 | 26.2% | 14.7% | ||
| Q3 25 | 30.1% | 14.5% | ||
| Q2 25 | 21.2% | 15.9% | ||
| Q1 25 | 4.1% | 17.1% | ||
| Q4 24 | 22.6% | 18.1% | ||
| Q3 24 | 29.5% | 15.6% | ||
| Q2 24 | 24.6% | 18.4% | ||
| Q1 24 | 19.3% | 18.7% |
净利率NBIXRBA
| Q4 25 | 19.1% | 9.1% | ||
| Q3 25 | 26.4% | 8.7% | ||
| Q2 25 | 15.6% | 9.3% | ||
| Q1 25 | 1.4% | 10.2% | ||
| Q4 24 | 16.4% | 10.4% | ||
| Q3 24 | 20.9% | 7.8% | ||
| Q2 24 | 11.0% | 10.1% | ||
| Q1 24 | 8.4% | 10.1% |
每股收益（稀释后）NBIXRBA
| Q4 25 | $1.49 | $0.53 | ||
| Q3 25 | $2.04 | $0.43 | ||
| Q2 25 | $1.06 | $0.53 | ||
| Q1 25 | $0.08 | $0.55 | ||
| Q4 24 | $1.00 | $0.58 | ||
| Q3 24 | $1.24 | $0.36 | ||
| Q2 24 | $0.63 | $0.54 | ||
| Q1 24 | $0.42 | $0.53 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $713.0M | $531.5M |
| 总债务越低越好 | — | $2.3B |
| 股东权益账面价值 | $3.3B | $5.6B |
| 总资产 | $4.6B | $12.1B |
| 负债/权益比越低杠杆越低 | — | 0.42× |
8季度趋势，按日历期对齐
现金及短期投资NBIXRBA
| Q4 25 | $713.0M | $531.5M | ||
| Q3 25 | $340.2M | $674.7M | ||
| Q2 25 | $264.0M | $710.2M | ||
| Q1 25 | $194.1M | $578.1M | ||
| Q4 24 | $233.0M | $533.9M | ||
| Q3 24 | $349.1M | $650.7M | ||
| Q2 24 | $139.7M | $599.5M | ||
| Q1 24 | $396.3M | $462.8M |
总债务NBIXRBA
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.6B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.8B | ||
| Q1 24 | — | $2.9B |
股东权益NBIXRBA
| Q4 25 | $3.3B | $5.6B | ||
| Q3 25 | $3.0B | $5.5B | ||
| Q2 25 | $2.7B | $5.5B | ||
| Q1 25 | $2.5B | $5.3B | ||
| Q4 24 | $2.6B | $5.2B | ||
| Q3 24 | $2.7B | $5.2B | ||
| Q2 24 | $2.5B | $5.2B | ||
| Q1 24 | $2.4B | $5.1B |
总资产NBIXRBA
| Q4 25 | $4.6B | $12.1B | ||
| Q3 25 | $4.3B | $12.2B | ||
| Q2 25 | $3.9B | $12.2B | ||
| Q1 25 | $3.7B | $11.9B | ||
| Q4 24 | $3.7B | $11.8B | ||
| Q3 24 | $3.5B | $11.9B | ||
| Q2 24 | $3.3B | $12.1B | ||
| Q1 24 | $3.5B | $12.0B |
负债/权益比NBIXRBA
| Q4 25 | — | 0.42× | ||
| Q3 25 | — | 0.47× | ||
| Q2 25 | — | 0.47× | ||
| Q1 25 | — | 0.50× | ||
| Q4 24 | — | 0.50× | ||
| Q3 24 | — | 0.52× | ||
| Q2 24 | — | 0.55× | ||
| Q1 24 | — | 0.58× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $388.4M | $255.2M |
| 自由现金流经营现金流 - 资本支出 | $386.0M | $186.5M |
| 自由现金流率自由现金流/营收 | 47.9% | 15.5% |
| 资本支出强度资本支出/营收 | 0.3% | 5.7% |
| 现金转化率经营现金流/净利润 | 2.53× | 2.33× |
| 过去12个月自由现金流最近4个季度 | $743.9M | $719.2M |
8季度趋势，按日历期对齐
经营现金流NBIXRBA
| Q4 25 | $388.4M | $255.2M | ||
| Q3 25 | $227.5M | $239.7M | ||
| Q2 25 | $102.0M | $326.5M | ||
| Q1 25 | $64.8M | $156.8M | ||
| Q4 24 | $242.5M | $184.5M | ||
| Q3 24 | $158.0M | $285.4M | ||
| Q2 24 | $64.6M | $337.3M | ||
| Q1 24 | $130.3M | $124.8M |
自由现金流NBIXRBA
| Q4 25 | $386.0M | $186.5M | ||
| Q3 25 | $214.3M | $188.5M | ||
| Q2 25 | $89.5M | $241.7M | ||
| Q1 25 | $54.1M | $102.5M | ||
| Q4 24 | $235.2M | $127.9M | ||
| Q3 24 | $149.9M | $248.5M | ||
| Q2 24 | $53.0M | $308.6M | ||
| Q1 24 | $119.1M | $79.6M |
自由现金流率NBIXRBA
| Q4 25 | 47.9% | 15.5% | ||
| Q3 25 | 27.0% | 17.3% | ||
| Q2 25 | 13.0% | 20.4% | ||
| Q1 25 | 9.4% | 9.2% | ||
| Q4 24 | 37.5% | 11.2% | ||
| Q3 24 | 24.1% | 25.3% | ||
| Q2 24 | 9.0% | 28.2% | ||
| Q1 24 | 23.1% | 7.5% |
资本支出强度NBIXRBA
| Q4 25 | 0.3% | 5.7% | ||
| Q3 25 | 1.7% | 4.7% | ||
| Q2 25 | 1.8% | 7.2% | ||
| Q1 25 | 1.9% | 4.9% | ||
| Q4 24 | 1.2% | 5.0% | ||
| Q3 24 | 1.3% | 3.8% | ||
| Q2 24 | 2.0% | 2.6% | ||
| Q1 24 | 2.2% | 4.2% |
现金转化率NBIXRBA
| Q4 25 | 2.53× | 2.33× | ||
| Q3 25 | 1.09× | 2.51× | ||
| Q2 25 | 0.95× | 2.97× | ||
| Q1 25 | 8.20× | 1.38× | ||
| Q4 24 | 2.35× | 1.56× | ||
| Q3 24 | 1.22× | 3.75× | ||
| Q2 24 | 0.99× | 3.04× | ||
| Q1 24 | 3.00× | 1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
RBA
| Buyer Revenue | $577.2M | 48% |
| Seller Revenue | $255.2M | 21% |
| CA | $199.0M | 17% |
| Other | $124.7M | 10% |
| AU | $47.3M | 4% |
